Oncolytic Virus Therapy Market
Oncolytic Virus Therapy Market by Product (HSV-Based Oncolytic Viruses, Adenoviruses-Based Oncolytic Viruses, and Others), By Application (Melanoma and Others) - Global Industry Share, Growth, Competitive Analysis and Forecast Period 2021-2027 Update Available - Forecast 2024-2030
Oncolytic virus therapy is based on the treatment through a virus that infects and kills cancer cells. The global oncolytic virus therapy market is anticipated to grow at a considerable CAGR of over 15% during the forecast period. The factors that are driving the growth of the market include the higher incidence and prevalence rate of cancer. Melanoma is one of the cancers that have been prevalent across the US region. The first oncolytic virus success over chemotherapy and radiotherapy has paved the way for developing them for other cancers.
Further, the side effects associated with conventional cancer therapies will also drive the growth of the market. Chemotherapy and radiation therapy cause certain side effects such as prolonged exposure to radiation may cause skin cancer. Melanoma is considered a serious type of skin cancer. As the prevalence of melanoma has been increasing, the demand for better and advanced treatment is increasing. Negative effects associated with conventional treatments such as chemotherapy are also shifting the market towards oncolytic virus therapy. As the demand for oncolytic virus therapy increases, biopharmaceutical companies are extensively adopting various strategies in order to commercialize a new oncolytic virus drug. Further, the companies are providing funding in order to boost research and development (R&D) in the field of oncolytic virus therapy.
However, some factors that are restraining the market growth include long complex clinical trials increase time to commercialization. A large number of oncolytic virus drugs in the pipeline is expected to create growth opportunities for the oncolytic virus therapy market across the globe.
Segmental Outlook
The global oncolytic virus therapy market is segmented on the basis of product, and application. On the basis of product, the market is further diversified into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, and others. Further, adenoviruses-based drugs have the least market share as these drugs are only commercialized in China. On the basis of application, the global oncolytic virus therapy market is further sub-divided into melanoma and others.
Global Oncolytic Virus Therapy Market Share by Application, 2020 (%)
Regional Outlooks
The global oncolytic virus therapy market is segmented into four major regions that include North America (the US and Canada), Europe (Germany, UK, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and Rest of the World (RoW). Among these, North America is estimated to hold a significant share in the oncolytic virus therapy market globally. The market growth is attributed to the extensive R&D in oncolytic virus therapy and the government support for innovative cancer therapies in this region.
Market Players Outlook
Many companies are investing in oncolytic virus therapy such as Amgen Inc., Merck KGaA, Oncolytic Biotech, PsiOxus Therapeutics, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, and Viralytics, among others. Various strategies are adopted by these market players to stay competitive in the market. For instance, in February 2018, Merck announced to invest $394 million for Viralytics, which is a company based in Australia for the development of oncolytic viruses to further boost cancer immunotherapy pembrolizumab (Keytruda). The company’s oncolytic drugs are in the clinical trial and once approved will change the cancer treatment market that in turn will significantly drive the growth of the oncolytic virus market.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global oncolytic virus therapy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global ONCOLYTIC VIRUS THERAPY MARKET
• Recovery Scenario of Global ONCOLYTIC VIRUS THERAPY MARKET
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Oncolytic Virus Therapy Market by Product
5.1.1. HSV-Based Oncolytic Viruses
5.1.2. Adenoviruses-Based Oncolytic Viruses
5.1.3. Others
5.2. Global Oncolytic Virus Therapy Market by Application
5.2.1. Melanoma
5.2.2. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbvie Inc.
7.2. Amgen Inc.
7.3. BenevirBiopharm, Inc.
7.4. Boehringer Ingelheim International GmbH
7.5. BioVex Inc.
7.6. Bristol-Myers Squibb Co.
7.7. Cold Genesys, Inc.
7.8. Creative Biolabs Inc.
7.9. Cynvec LLC
7.10. DNAtrix Inc.
7.11. F. Hoffmann-La Roche Ltd.
7.12. Genelux Corp.
7.13. MediGene AG
7.14. Merck& Co., Inc.
7.15. Neotropix, Inc.
7.16. Oncolys BioPharma Inc.
7.17. Oncolytics Biotech, Inc.
7.18. Oncorus Inc.
7.19. Otsuka Pharmaceuticals Co. Ltd
7.20. PsiOxus Therapeutics Ltd
7.21. Shanghai Sunway Biotech Co. Ltd
7.22. Silajen Biotherapeutics, Inc.
7.23. Sorrento Therapeutics Inc.
7.24. Takara Bio, Inc.
7.25. Targovax
7.26. Theravir
7.27. TILT Biotherapeutics Ltd.
7.28. Transgene SA
7.29. VCN Biosciences SL
7.30. Viralytics Ltd
7.31. Vyriad
1. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS,2020-2027 ($ MILLION)
2. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET BY PRODUCT,2020-2027 ($ MILLION)
3. GLOBAL HSV-BASED ONCOLYTIC VIRUSES MARKET BY REGION,2020-2027 ($ MILLION)
4. GLOBAL ADENOVIRUSES-BASED ONCOLYTIC VIRUSES MARKET BY REGION,2020-2027 ($ MILLION)
5. GLOBAL OTHER ONCOLYTIC VIRUS THERAPY MARKET BY REGION,2020-2027 ($ MILLION)
6. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET BY APPLICATION INDUSTRY, 2020-2027 ($ MILLION)
7. GLOBAL MELANOMA CANCER VIRUS THERAPY MARKET BY REGION,2020-2027 ($ MILLION)
8. GLOBAL OTHERS VIRUS THERAPY MARKET BY REGION,2020-2027 ($ MILLION)
9. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
10. NORTH AMERICAN ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
11. NORTH AMERICAN ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
12. NORTH AMERICAN ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
13. EUROPEAN ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
14. EUROPEAN ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
15. EUROPEAN ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
16. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
17. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
18. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
19. REST OF THE WORLD ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2020-2027 ($ MILLION)
20. REST OF THE WORLD ONCOLYTIC VIRUS THERAPY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
1. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SHARE BY PRODUCT, 2020 VS 2027 (%)
2. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
3. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027, (%)
4. GLOBAL HSV-BASED ONCOLYTIC VIRUSES MARKET BY REGION, 2020 VS 2027 (%)
5. GLOBAL ADENOVIRUSES-BASED ONCOLYTIC VIRUSES MARKET BY REGION, 2020 VS 2027 (%)
6. GLOBAL OTHER VIRUSE THERAPY MARKET BY REGION, 2020 VS 2027 (%)
7. GLOBAL MELANOMA CANCER VIRUSE THERAPY MARKET BY REGION, 2020 VS 2027 (%)
8. GLOBAL OTHER CANCER VIRUSE THERAPY MARKET BY REGION, 2020 VS 2027 (%)
9. US ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
10. CANADA MARKET ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
11. UK ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
12. GERMANY ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
13. SPAIN ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
14. FRANCE ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
15. ITALY ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
16. REST OF EUROPEON COLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
17. INDIA ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
18. CHINA ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
19. JAPAN ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
20. REST OFASIA-PACIFICONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
21. REST OF WORLD ONCOLYTIC VIRUS THERAPY MARKET SIZE, 2020-2027 ($ MILLION)
